Clinical Trial Search Results

A scientist pointing to an image of a DNA chain.

Clinical Trial Search Results

Showing 1-9 out of 318 results.
NCT04849728

'Inventiva S.A. / “A randomised, double-blind, placebo- controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis”
'

Icon for trial | 337HNAS20011 'Inventiva S.A. / “A randomised, double-blind, placebo- controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and f

This study is currently enrolling.

Inventiva S.A. (the Sponsor) is running a research study to see if an investigational drug named lanifibranor, not yet approved for marketing, will help in the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) and ...

NCT04639050

: BP42155: A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease (Brainshuttle AD)

Icon for trial | BP42155 : BP42155: A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in P

This study is currently enrolling.

Trontinemab is an experimental drug that is being developed for the possible treatment of AD. Trontinemab combines an anti-amyloid antibody with a brain shuttle module which helps to deliver the antibody to the brain. It works ...

NCT05629585

: D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disease in Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (TROPION-Breast03)

Icon for trial | D926XC00001 : D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disea

This study is currently enrolling.

We are doing this study to learn more about whether an investigational drug called datopotamab deruxtecan (also called Dato-DXd), either alone or in combination with another investigational drug called durvalumab, will work and ...

NCT06132958

: MK2870-005/ENGOT-en23/GOG3095 A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy

Icon for trial | MK2870-005/ENGOT-en23/GOG3095 : MK2870-005/ENGOT-en23/GOG3095 A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants Wi

This study is currently enrolling.

The purpose of this trial is to: Test the safety of the trial drug, MK-2780: see how well the trial drug works, see how your body handles the trial drug. See how well MK-2870 works compared to the 2 standard chemotherapies. See ...

NCT06016738

: OP-1250-301 A Phase 3 Randomized Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 inhibitor Therapy (OPERA-01)

Icon for trial | OP-1250-301 : OP-1250-301 A Phase 3 Randomized Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 inhibitor Therapy (OPERA-01)

This study is currently enrolling.

The goal of this study is to test if the study drug, OP-1250, is better or worse than the usual approach for your type of breast cancer. The usual approach, also known as the “standard of care”, is defined as care most people ...